RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

NK Securities vs ProopCo

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

NKSC

NK Securities

PRPC

ProopCo

NK SECURITIES

METRIC

PROOPCO

0/100TIE

TRUST SCORE

TIE0/100

0/5TIE

RATING

TIE0/5

—

PROFIT SPLIT

—

MAX FUNDING

—

MIN COST

—

PAYOUT DAYS

—

PASS RATE

—

0TIE

REVIEW COUNT

TIE0

NK SECURITIES DETAILS

STEPS: -phase

PROOPCO DETAILS

STEPS: -phase
MARKETS: Forex, Indices, Crypto

NK Securities PROS

+Placeholder pro — no data provided beyond country; no metrics to evaluate
+Placeholder pro — no data provided beyond country; no metrics to evaluate
+Placeholder pro — no data provided beyond country; no metrics to evaluate
+Placeholder pro — no data provided beyond country; no metrics to evaluate

NK Securities CONS

−No trading metrics were provided, preventing any comparison to industry averages
−India-based prop firms may face additional regulatory uncertainty for international traders
−Absence of data on profit split, funding, or payouts limits trader confidence

ProopCo PROS

+Offers Forex, Indices, and Crypto markets, providing moderate asset class diversity
+Placeholder pro — limited data prevents further above-average metric identification
+Placeholder pro — limited data prevents further above-average metric identification
+Placeholder pro — limited data prevents further above-average metric identification

ProopCo CONS

−Iran is subject to extensive international sanctions, creating serious legal and payment risks for traders
−No profit split, funding cap, drawdown, or payout data is available for comparison
−Regulatory and banking restrictions may make funding and withdrawals extremely difficult

PROPDNA VERDICT